No Data
Stephens Downgrades Elevation Oncology to Equal Weight From Overweight, Adjusts Price Target to $1 From $5
Elevation Oncology: Strategic Shift to EO-1022 Amidst EO-3021 Discontinuation Justifies Hold Rating
Piper Sandler Downgrades Elevation Oncology(ELEV.US) to Hold Rating, Cuts Target Price to $0.7
William Blair Maintains Elevation Oncology(ELEV.US) With Buy Rating
H.C. Wainwright Maintains Elevation Oncology(ELEV.US) With Buy Rating, Cuts Target Price to $1
Elevation Oncology Plunges 42% on Ending Development of Lead Drug
